Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population-Reference-Cited by-同舟云学术

Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population

Published:2018-09-04 Issue:9 Volume:320 Page:929
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Kozlowski Steven¹,Birger Noy²,Brereton Stephaeno²,McKean Stephen J.²,Wernecke Michael²,Christl Leah¹,Kelman Jeffrey A.³

Affiliation:

1. Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

2. Acumen LLC, Burlingame, California

3. Centers for Medicare & Medicaid Services, Washington, DC

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference6 articles.

1. Biosimilars and the European experience: implications for the United States.;Megerlin;Health Aff (Millwood),2013

2. Biosimilar competition: lessons from Europe.;Grabowski;Nat Rev Drug Discov,2014

3. US Food and Drug Administration. Center for Drug Evaluation and Research list of licensed biological products. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdf. Accessed June 4, 2018.

4. RoyzmanI. United States: the value of being highly similar: first US biosimilar. http://www.mondaq.com/unitedstates/x/391742/food+drugs+law/The+Value+of+Being+Highly+Similar+First+US+Biosimilar. Accessed February 18, 2018.

5. FDANews. Sandoz launches Zarxio at 15 percent lower price than Neupogen. https://www.fdanews.com/articles/173036-sandoz-launches-zarxio-at-15-percent-lower-price-than-neupogen. Accessed February 18, 2018.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019;Journal of Managed Care & Specialty Pharmacy;2024-01-01

2. Uptake of Biosimilar Among Privately Insured Patients Undergoing Infliximab Treatment;Medical Care;2023-08-10

3. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019;JAMA Network Open;2021-11-23

4. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition;JAMA Network Open;2021-11-15

5. Cost to Medicare of Delayed Adalimumab Biosimilar Availability;Clinical Pharmacology & Therapeutics;2021-07-06